The major depressive disorder market attained a value of USD 6.42 Billion in 2025. The market is further expected to grow in the forecast period of 2026-2035 at a CAGR of 5.30%, to reach USD 10.76 Billion by 2035.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
5.3%
Value in USD Billion
2026-2035
*this image is indicative*
Major depressive disorder (MDD) is characterized by persistently low and depressed mood along with a loss of interest in everyday activities. The incidence rate is rising in the younger population due to alcohol and drug abuse. According to the Mental Health America prevalence data of 2023, 16.39% of youth aged between 12-17 years suffered from at least one major depressive episode (MDE) in the previous year. The state prevalence of MDE in youth was reported to be 12.57% in New Jersey and 21.13% in Oregon.
Major depressive disorder is highly prevalent in women, owing to several factors such as hormonal differences, different psychosocial stressors, and childbirth effects. The average onset of this psychiatric disorder is estimated to be 40 years . The rising prevalence of mental illnesses is projected to boost the major depressive disorder market growth in the forecast period.
The market is witnessing steady growth supported by the surge in drug approvals by the health regulatory agencies. For instance, in October 2023, the United States Food and Drug Administration (FDA) approved gepirone ER, marketed as Exxua, to treat major depressive disorder (MDD). The medication developed by Fabre-Kramer Pharmaceuticals, Inc. (a United States pharmaceutical company) targets the serotonin 1A receptor, a key mood regulator. Exxua is the only drug that selectively stimulates the receptor without any adverse symptoms of weight gain or sexual dysfunction. The availability of such drugs in the market will positively influence the market landscape.
The major depressive disorder market demand is further bolstered by the rising geriatric population at a higher risk of developing mental disorders. The rising mental health campaigns and initiatives by the government to support patients suffering from clinical depression are also anticipated to accelerate the market growth in the forecast period.
"Global Major Depressive Disorder Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The market for treating major depressive disorder (MDD) can be segmented by product type, including benzodiazepines, antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other medications. This market segment comprises the pharmacological options available for managing MDD.
Market Breakup by Treatment Type
The major depressive disorder market report includes segmentation based on treatment types. It includes medication, psychotherapy, and brain stimulation therapies. Under medication, options include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). This market segment offers a range of interventions available for managing MDD, aligning with patients’ needs and preferences.
Market Breakup by Diagnosis Tests
Based on diagnostic tests, the major depressive disorder market share includes psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools. This market segment shows the approaches to diagnosing MDD, which forms an essential part of effective treatment planning.
Market Breakup by Distribution Channel
Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels. The diverse network of these channels helps in accommodating the diverse clinical needs of patients suffering from major depressive disorder.
Market Breakup by End User
Major end users of the major depressive disorder market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs). Mental health centers provide mental health care, such as diagnosis and therapy to MDD patients.
Market Breakup by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America dominates the regional market, attributed to the high prevalence rates of major depressive disorder. Rapid technological advancements in the healthcare sector and the rise in the geriatric population base, which is more susceptible to develop the condition. Such factors are expected to further bolster the market growth in the region.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 6.42 Billion in 2025 driven by the rising prevalence of major depressive disorder across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.30% during the forecast period of 2026-2035, likely to reach a market value of USD 10.76 Billion by 2035.
The market demand is driven by the rising geriatric population at a higher risk of developing mental disorders.
One of the significant market trends revolves around the surge in drug approvals by health regulatory agencies. For instance, in October 2023 , the United States Food and Drug Administration (FDA) approved Fabre-Kramer Pharmaceuticals, Inc.’s gepirone ER (marketed as Exxua) to treat major depressive disorder (MDD).
Based on the product type, the market is segmented into benzodiazepines, antidepressant drugs, SSRIs, SNRIs, and other medications.
Based on the treatment type, the market is segmented into medication, psychotherapy, and brain stimulation therapies. Medications include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).
Major end users of the market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs).
Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels.
Diagnostic tests available in the market include psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are Lundbeck, AbbVie, Relmada Therapeutics, Axsome Therapeutics, Alkermes, Intra-Cellular Therapies, Allergan plc, Pfizer Inc., Sanofi S.A., Johnson & Johnson, Merck & Co., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AstraZeneca Plc, and GSK plc.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis Tests |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share